Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Longeveron Inc.

Get SEC filing alerts via email and in your feed for Longeveron Inc.

LGVN

Longeveron Inc.

About Longeveron Inc.

Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines, primarily using allogeneic mesenchymal stem cells like Lomecel-B. Its focus includes treatments for hypoplastic left heart syndrome, Alzheimer’s disease, and aging-related frailty. The company aims to advance cell therapies through clinical trials, leveraging proprietary technologies and strategic collaborations to address unmet medical needs in regenerative medicine.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Longeveron Inc.

1
1
Longeveron Inc. Longeveron Reports Q1 2026 Financial Results with Revenue Increase and Net Loss Improvement

Via official filing (AI summary) | 22 days ago | 0 comments

2
1
Longeveron Inc. Longeveron Inc. Reports $1.2 Million Revenue Decline and $22.7 Million Net Loss in Annual Filing

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Longeveron Inc. Longeveron Reports 82% Revenue Decline in Q3 2025, Net Loss Increases

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Longeveron Inc. Longeveron Reports Decline in Revenue and Increased Net Losses for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Longeveron Inc. Longeveron Reports 30% Revenue Decline and $5 Million Net Loss in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Longeveron Inc. Longeveron Reports 237% Revenue Growth to $2.4 Million in 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Longeveron Inc. Longeveron Reports 415% Revenue Growth, Net Loss Reduction in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments